Boy this is a super fun post. I was most certainly jacked up. when I read this back i realize damn I should be getting paid to do this. 1- WDAY sell at $256 smart--->has not moved. $238 now 2- RDW buy $5.45 / $15.23 now 3- LRN buy $73 / $136 now 4- DDOG buy $105 / $146 now big downgrade today 5- KYN buy $10.14 / $12.42 now with now 7.75% yield 6- LUMN buy $1.59 / $4.51 now (topped out at $7) 7- SGHC buy $3.87 / $11 now 8- SE buy $77 / $148 now 9-EH buy $12.79 / $17 now 10- COHR buy $70 / $90 now ignore the WWW short that did not work out well./// 1 post 10 HUGE winners. GBA #1
Roth Capital views DoubleDown acquisition of WHOW Games as a strategic positive » 13:04 DDI Trump says will be imposing 50% tariff on copper » Kuwait fund sold $3.1B Bank of America stake in block trade, Bloomberg says » 12:40 BAC
What is our entry price here? IMRX Immuneering Corporation $3.98-0.07(-1.73%)1:18 PM 07/08/25 NASDAQ |$USD |Realtime
Near-Term Milestone Expectations IMM-1-104 Initial progression-free survival data from the IMM-1-104 Phase 2a trial expected in the second quarter of 2025. Additional IMM-1-104 combination arms in planning. Initiation of Phase 3 trial of IMM-1-104+mGnP in first-line pancreatic cancer planned for 2026. First Quarter 2025 Financial Highlights Cash Position: Cash and cash equivalents as of March 31, 2025, were $35.9 million, compared with $36.1 million as of December 31, 2024. Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2025 were $11.5 million compared with $11.2 million for the first quarter of 2024. The increase in R&D expenses was primarily attributable to higher clinical costs related to the Company’s lead program. General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2025 were $4.0 million compared with $4.1 million for the first quarter of 2024. The decrease in G&A was primarily attributable to a decrease in the Company’s employee-related costs in connection with the general and administrative functions supporting the business. Net Loss: Net loss attributable to common stockholders was $15.0 million, or $0.42 per share, for the first quarter ended March 31, 2025, compared to $14.3 million, or $0.49 per share, for the first quarter ended March 31, 2024. 2025 Financial Guidance Based on cash and cash equivalents, as of March 31, 2025, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2026.
Based on4Wall Street analysts offering 12 month price targets for Immuneering in the last3 months. The average price target is$10.88 with a high forecast of$21.00 and a low forecast of $3.50. The average price target represents a173.37%change from the last price of$3.98.
I have a terrible tooth situation- mucho pain kept me up all night today I bled the gum and the blood flowed. Either I cure myself of this abscess now or it's dentist time. They say this cannot be cured at home I have done it before. And lost before. But you can also die from this. I think my grandpa did. " It's important to cry once every investing day. " This is a known fact.